SK Hynix Shelves Solidigm Listing Review as Moderna Slides
SK Hynix seeks other financing after halting its Solidigm listing review, while Moderna extends its decline and asset managers give back gains.

SK Hynix shares fell around 3% in Seoul after the company halted its review of a potential U.S. listing for Solidigm and said it would seek other financing options.
SK Hynix’s decision to stop reviewing a potential U.S. listing for Solidigm leaves the South Korean chipmaker seeking another financing route as it needs substantial funding for a U.S. semiconductor fabrication plant. Its shares fell around 3% in Seoul following the decision.
The financing setback coincided with a sharp reversal in Moderna shares and a move into U.S. government debt. But Friday’s closing figures showed that the earlier rally in asset managers accompanying lower Treasury yields did not hold across the group.
Solidigm decision shifts attention to financing
SK Hynix cited market conditions and share-price trends in ending the listing review, according to Baystreet. The company said it would explore other financing options.
The decision concerns a potential source of capital, rather than an announced cancellation of the U.S. factory. That distinction matters: the construction funding requirement remains, while the prospective listing route is no longer being pursued under the review.
For investors, the next financing choice will matter alongside the factory itself. Raising debt, using internal resources or bringing in outside capital would have different consequences for the balance sheet and shareholders. SK Hynix has said it will seek alternatives, not selected one of those routes.
Moderna’s study result meets a stock reversal
For investors, the next financing choice will matter alongside the factory itself.
Moderna (MRNA) closed Thursday down 17.57% at $202.63 after a rally that began around $50 and reached a peak of $254.48. At the most recent close on Friday, October 23, its shares fell another 1.25%.
The reversal came as ESMO posted the full study dataset for intismeran autogene, the cancer vaccine Moderna is developing with Merck. The reported result was a 42% reduction in the risk of melanoma returning or death.
That figure describes the study’s recurrence-or-death outcome; it is not a share-price forecast or a statement that melanoma was eliminated. The clinical result and the stock’s decline therefore answer different questions: one concerns treatment performance, while the other reflects what investors were willing to pay after the earlier rally.
Merck shares also finished Friday lower, declining 1.34%.
Lower yields fail to sustain asset-manager gains
The 10-year Treasury yield moved below 5.0% on Thursday, reaching a level not seen in a month as weakness in artificial-intelligence suppliers drove demand for government bonds. Bond prices and yields move in opposite directions.
KKR, Blackstone, BlackRock, Brookfield and T. Rowe Price initially rallied alongside the decline in yields. Friday’s closing moves, recorded as of 20:00 GMT, showed a less uniform response.
KKR fell 1.88%, Blackstone lost 0.66%, BlackRock declined 1.67% and Brookfield dropped 1.28%. T. Rowe Price was the exception, gaining 0.72%. The divergence limits the earlier rally’s usefulness as a broad signal of sustained buying across asset managers.
Key facts
- SK Hynix financing: Shares fell around 3% in Seoul after the Solidigm U.S. listing review was halted.
- Moderna shares: MRNA closed Thursday at $202.63, down 17.57%; Friday’s most recent close showed a further 1.25% decline.
- Cancer vaccine result: Intismeran autogene reduced the risk of melanoma returning or death by 42%.
- Treasury yield: The 10-year yield broke below 5.0% on Thursday, a level not seen in a month.
Sources
Photo: analogicus · Pixabay Content License — source


